KR100516341B1 - Compositions for regulating desire for smoking - Google Patents

Abstract

The present invention provides a method for suppressing smoking desire in a situation in which smoking cessation is required in daily life; (2) intentional smoking cessation or insulation (freely); And (3) a very safe and dependence-free smoking desire suppressing composition that allows for the eradication of smoking habits. It is also to provide a method for smoking cessation or insulation by administering a theanine-containing composition to an individual.

Description

Smoking desire suppression composition {COMPOSITIONS FOR REGULATING DESIRE FOR SMOKING}

The present invention relates to a smoking cessation inhibiting composition containing theanine and a method of smoking cessation or insulation comprising administering theanine-containing composition to an individual.

Smoking has been known to be a major cause of diseases such as lung cancer, bronchitis, and coronary or peripheral arterial disease. Each chemical contained in tobacco has already been recognized as a carcinogen, and recently, carcinogenicity by secondhand smoke has been revealed, and in the United States, smokeless chewing tobacco and snuff have been recorded on the list of carcinogens. Among the components contained in tobacco, nicotine, a colorless volatile liquid alkaloid, has a soothing effect, arousal effect, and pleasant effect, and nerves such as the cerebral nerve, cerebellum, and spinal cord. It has high toxicity that irritates and paralyzes tissue. Therefore, reports on the development of lung cancer, pharyngeal cancer, esophageal cancer and gastric cancer have continued.

In addition, since nicotine has a mental dependency, continuous intake of nicotine by smoking or the like can cause nicotine dependency. For example, when heavy smokers (heavy smokers) quit smoking, withdrawal symptoms appear in a short period of time, and the desire to smoke increases. If a smoker cannot tolerate the smoking desire and consume more nicotine to avoid the symptoms and pain, his health becomes more dangerous.

In such a situation, smoking cessation and insulation campaigns are carried out worldwide, and the smoking population tends to decrease every year. Smoking tends to be restricted in public facilities and transportation, so smokers often have to quit. However, in many cases, relieving smoking habits can cause mental and physical pain, and sudden decreases in nicotine intake can cause severe withdrawal symptoms. For this reason, there is an urgent need for a method that has an effect on gradually quitting smoking or insulating without causing any problems.

As such a method, food and pharmaceuticals such as nicotine gum and various plant effluents, minerals containing candy, drops or gums (Japanese Patent Laid-Open No. 4-46119, Japanese Patent Laid-Open No. 61-63243, Japanese Patent Laid-Open No. 62-296840, Japanese Patent Laid-Open Nos. 62-296840, 8-308544, 82-42582, 7-18076, and 48-85722. In addition, a method of causing discomfort by ingesting various chemicals simultaneously with tobacco smoke using a pipe or the like, and a method of promoting smoking cessation by absorbing nicotine into the body by nicotine pads or nicotine nasal sprays have been used. The principles of smoking cessation or isolation by these methods fall into three categories: (1) suppression of the need for smoking by paralysis, such as taste, (2) promoting detoxification / secretion of nicotine in the body, and (3) tobacco substitutes. By supply of nicotine. However, when nicotine is absorbed by the epidermis or the like, nicotine eventually exists in the body, and this method cannot be said to be good for health. There is also a risk for the dependence of the tobacco substitutes used, even if a reduction in the smoking desire is achieved. In addition, the above-mentioned food and the like, the effect is weak, and generally will not satisfy the taste of smokers generally accustomed to nicotine, it will not be able to fundamentally suppress withdrawal symptoms. Therefore, smokers often do not avoid smoking, so the efficacy often has some limitations.

1 shows the change in the nicotine concentration in the smoker in 1 day.

2 shows the result of preliminary investigation of test 2 immediately after the vapor phase.

3 shows the results of test 2 immediately after the vapor phase.

4 shows the results of preliminary investigations of the daytime test.

5 shows the results of the daytime test.

FIG. 6 shows the results of the continuous intake test within 1 day, where bars in the graph represent smoking cigarettes (number) and solid squares (number) of the test substance. In addition, the number 1 of the horizontal axis of the graph represents the results of any one day without ingestion of the test substance, and 2 to 4 are the results of each day of the individual 3 days of the test.

FIG. 7 shows the results of the continuous intake test during the day, where the bars in the graph represent the number of smoking cigarettes (number) and the black squares show the number of intakes (test) of the test substance.

FIG. 8 shows changes in blood nicotine concentration when chewing tablets of L-theanine combination are absorbed orally by mucosal oral mucosa.

Fig. 9 shows the change in the craving for smoking and the change in the concentration of theanine in the blood when the subject is ingested 87 mg of theanine.

FIG. 10 shows a change in the desire for smoking and a change in blood theanine concentration when the subject is ingested 200 mg of theanine.

Best Mode for Carrying Out the Invention

Smoking desire suppressing compositions of the present invention (hereinafter referred to as compositions) are well suited for treating any condition in which withdrawal symptoms (hereinafter referred to as withdrawal symptoms) based on tobacco or nicotine may occur. The expression of the desired effect of the composition of the present invention is based on the smoking desire inhibitory action first found in theanine contained in the composition.

The phrase " inhibition of smoking desire " refers to suppressing the smoking desire, for example, by reducing the withdrawal symptoms and suppressing the onset of the withdrawal symptoms.

The term "nicotine" refers to an active ingredient in tobacco products. Nicotine is a drug that produces dependence, is easily absorbed into the interior, and is known to reach the brain after about 8 seconds. Nicotine affects the pleasure centers of the cerebral (central nervous system), providing pleasure. If the desire to smoke continues, so-called cigarette or nicotine dependence can be caused, in which case certain changes occur in the brain and, when quitting, deteriorates body control.

On the other hand, "theanine" used in the present invention is a glutamic acid derivative (γ-glutamyl ethylamide) and is an amino acid component naturally contained in tea leaves. The mechanism of action of inhibitory action of smoking desire by theanine found for the first time in the present invention is not yet known and is not generally expected from various known physiological actions, but as shown in the following examples, nicotine-dependent smokers The test results confirmed the relationship between theanine blood concentration after theanine administration and the inhibitory effect of withdrawal symptoms. Therefore, delivery of theanine to the brain after administration would be somewhat related to effect expression.

The method for producing theanine used in the present invention is a method for extracting from tea leaves, a method for obtaining theanine by an organic synthesis method [ Chem. Pharm. Bull. , 19 (7), 1301-1307 (1971); A method of obtaining theanine, which comprises treating a mixture of glutamine and ethylamine with glutaminase (Japanese Patent Application Laid-Open No. 7-55154), culturing a group of tea cultured cells in a medium containing ethylamine, thereby Etalamine hydrochloride in the above-mentioned method disclosed in Japanese Patent Application Laid-Open No. 5-123166, Japanese Patent Application Laid-Open No. 7-55154 or Japanese Patent Application Laid-Open No. 5-123166 while increasing the theanine accumulation amount It may be any of known methods, including a method for obtaining theanine for substituting ethylamine with an ethylamine derivative such as the like. In addition, theanine used in the present invention may be in any form such as tablets, crudes, extracts and the like. In addition, commercially available products [SUNTHEANINE (registered trademark), Taiyo Kagaku Co., Ltd. Manufacture] can be used. Incidentally, the term "tea leaves" as used herein includes the leaves of green tea, oolong tea and black tea.

In addition, any of L-theanine, D-theanine and DL-theanine can be used, of which L-form is preferable in the present invention because it is recognized as a food additive and economically useful.

Theanine content in the composition of the present invention is not particularly limited as long as the desired effect of the present invention is achieved. Theanine content is usually preferably 0.001 to 100% by weight, more preferably 0.01 to 100% by weight, particularly preferably 0.1 to 100% by weight.

The theanine detection method in the composition of the present invention is not particularly limited. The method includes derivatization in a pre-column with orthophthalaldehyde (OPA), followed by separation by high performance liquid chromatography (HPLC) using an ODS column and quantitative detection in a fluorescence detector, or the ODS column It is preferred to include separation by HPLC, and detection and quantification at a wavelength of 210 nm.

Moreover, various other ingredients may be used with theanine as appropriate in the compositions of the present invention. Other ingredients are not particularly limited and include, for example, amino acids, vitamins, minerals, other functional materials, and the like.

The amino acid is not particularly limited, and examples thereof include glutamine, glutamic acid, tryptophan, alanine, arginine, aspartic acid, threonine, serine, γ-aminobutyric acid, taurine, thiotaurine, hypotaurine, and the like.

Examples of the vitamins include vitamin A, vitamin B ₁ , vitamin B ₂ , vitamin B ₆ , vitamin B ₁₂ , vitamin C, vitamin D, vitamin E, vitamin K, folic acid, nicotinic acid, lipoic acid, pantothenic acid, biotin, ubiquinone , Prostaglandins and the like, and derivatives of these vitamins are included, but are not limited to these.

The minerals include, but are not limited to, calcium, iron, magnesium, copper, zinc, selenium, potassium, and the like, for example.

In addition, the other functional material, for example, St. John's wort, herbs such as chamomile, herbal plants such as Kimnema / Garcia, Eucommia ulmoides and Korean ginseng or its Extracts, animal extracts such as placenta, dietary fiber, soy protein, diet sweeteners, caffeine and the like, but are not limited to these.

As for the form of the composition of the present invention, a food composition or a pharmaceutical composition is preferred in view of suitability for daily use.

The food composition of the present invention encompasses not only theanine-containing foods but also theanine-containing food additives. When preparing a food composition, theanine may be added to the following foods, for example.

Specifically, theanine may be added to solid food or liquid food. Solid foods are not particularly limited, but preferably include sweets, candies, chocolates, gums, crackers, biscuits, cookies, paste products, processed soy products, mousse, jelly, yogurt, cold confections, cakes, breads and the like. Liquid foods are also not particularly limited, and theanine is preferably concentrated fruit juice, concentrated reduction juice, fresh juice, mixed fruit juice, fruit juice containing fruit kernel, fruit juice containing beverage, fruit / vegetable juice, vegetable juice, carbonated It can be added to beverages, soft drinks, mineral water, milk, milk beverages and coffee beverages, or alcoholic beverages such as Japanese shake, beer, wine, cocktails, shochu and whiskey.

Among these, agents suitable for absorption through the oral mucosa are preferred. Particular preference is given to solid foods, such as refined confectionery, candy or gums, for example in the form which may remain in the mouth for a certain period of time. In solid foods, theanine dissociates gradually in the mouth. By such action, theanine is absorbed internally primarily through the oral mucosa. When theanine is absorbed through the oral mucosa, theanine will be transmitted to the brain more efficiently than if it is through the portal system, thereby allowing its action to manifest. On the other hand, when considering oral intake, it may be difficult to use the gum depending on the type of occupation, and the situation of the workplace, the form of tablet tasks or candy is more preferred. For these various forms, those suitable for absorption through the intraoral mucosa are preferred formulations which remain in the mouth for at least 3 minutes upon oral ingestion. Moreover, the size and shape are preferably those that are difficult to chew and swallow.

When the composition of the present invention is prepared as a pharmaceutical composition, its form based on known pharmaceutical compositions may be any of solutions, suspensions, powders, solid molded articles, and the like, but is not particularly limited thereto. . Therefore, the pharmaceutical compositions are provided as tablets (including tablets as well as troche, etc.), capsules, powders, granules, health care drinks and the like. Pharmaceutical compositions can also be used with other agents.

Moreover, for food compositions, those suitable for absorption through the oral mucosa are preferred. Thus, from the standpoint of absorbing theanine internally without intervening the hepatic system, tablets, in particular pills or sublingual tablets, are preferred as forms of the pharmaceutical composition of the present invention. Sublingual tablets are not particularly limited as long as the tablets can be placed under the tongue. It is preferred that the tablets disintegrate, preferably within 3 to 6 minutes, so that theanine can dissociate rapidly into the sublingual mucosa. The disintegrating means is not particularly limited and conventional methods can be followed. With the use of sublingual tablets, theanine is absorbed through the sublingual mucosa and can be efficiently transported to the brain, so sublingual tablets are particularly suitable for the treatment of acute withdrawal symptoms or for the treatment of transient nicotine needs.

The manufacturing method of the composition of this invention is not specifically limited, The powder mixing method of theanine and other raw materials; Dissolving theanine and other raw materials in a solvent to obtain a mixed solution; And a method of freeze drying the mixed solution; General methods of preparing foods and drugs, such as spray drying the mixed solution, may be used. For example, pharmaceutical compositions can be prepared by mixing theanine with vehicles, carriers, binders, stabilizers and the like that are known in the art.

By using the composition of the present invention, for example, (1) it can be carried out to suppress the desire to smoke in a situation where smoking cessation is necessary in everyday life. For individuals with smoking habits that do not wish to resolve their smoking habits, it may be very difficult to quit smoking during a given time, whether long or short term. Situations in which smoking cessation is required include, for example, using public transport such as airplanes, and situations in hospitals. In such a case, the desire for smoking can be effectively suppressed by using the composition of the present invention, so that smoking cessation can be made without any problem. However, the inhibitory action does not last unprofitably for a long time, and smoking can resume once the time for which smoking cessation is necessary has elapsed. Such suppression of smoking desire and elasticity of smoking resumption is a very superior aspect compared to suppressing smoking desire by conventional nicotine substitutes such as nicotine pads which can ineffectively support the inhibitory effect on smoking desire. In particular, in recent years, as the understanding of tobacco consumption and the accompanying deleterious effects of nicotine inhalation has advanced, the need for smoking cessation is increasing, and thus the use and implementation of the composition of the present invention mentioned above is particularly preferred.

In addition, by using the composition of the present invention, it is possible to (2) intentionally (freely) quit smoking or insulating. When a person with a smoking habit who does not wish to relieve the habit attempts to quit or insulate according to a doctor's instruction, or when an individual wishes to quit smoking while in contact with an infant, etc. By using it, it can be effectively suppressed, and thus can be non-smoking or insulated in the same manner as mentioned above. In addition, in the same manner as mentioned above, when smoking cessation or insulation is no longer needed, smoking can be resumed at a time.

In addition, by continuously ingesting the composition of the present invention, (3) smoking habit can be eradicated. Among the smokers who start quitting, there are generally a few who are confident of quitting. This is especially the case if the individual has given up smoking in some of the past hard situations due to painful withdrawal symptoms after starting smoking. However, since smoking desire can be effectively suppressed by using the composition of the present invention, smoking cessation can continue without any problem and ultimately eradicate smoking habits.

Moreover, by using the composition under appropriate instructions and counseling on quitting smoking, additional effects can be expected. To date, nicotine preparations such as nicotine gum and nicotine pads have been used as anti-smoking supplements, for indications and the like. However, nicotine is very toxic and is prohibited in individuals with unstable eye or laryngitis, individuals with myocardial infarction, pregnant women, and women who may be pregnant. The anti-smoking supplement may be prescribed for the purpose of allowing an individual who wishes to quit smoking to use it alone under appropriate instructions. If another person uses anti-smoking supplements, it is not necessarily safe. In particular, if anti-smoking supplements were delivered to individuals forbidden by hand-over, there was a potential risk to the situation. Moreover, since nicotine preparations act as temporary substitutes for nicotine sources that have been ingested from tobacco, dependence on nicotine preparations may occur.

Since theanine used in the composition of the present invention is the fully safe ingredient mentioned below, and there is no possibility of theanine dependence, addicted smokers can safely and effectively eliminate smoking habits by using the composition under the direction for quitting smoking.

As described above, by using the compositions of the present invention, the various use implementations mentioned above can be achieved because it is possible to prevent, alleviate or eliminate withdrawal symptoms caused by smoking cessation or insulation.

The present invention also provides a smoking cessation or insulation method comprising administering a theanine containing composition to an individual (human). In this method, the use of the composition of the present invention is preferred. The effective dosage of theanine to achieve the desired effect of the invention in such use embodiments of the compositions of the invention is generally 0.1 to 50 mg / kg body weight per day, more preferably 0.5 to 20 mg / kg body weight , Even more preferably 1 to 20 mg / kg body weight, particularly preferably 4 to 20 mg / kg body weight.

The timing of use of the composition of the present invention is not particularly limited. For example, the composition may be administered in advance when withdrawal symptoms are expected to occur by smoking cessation or isolation, or may be administered while withdrawal symptoms occur. In a more specific embodiment, if the smoker wishes to temporarily treat the withdrawal symptoms, the composition is administered to the smoker before or during the withdrawal symptoms, wherein the smoker preferably smokes during a cigarette deprivation or nicotine deficiency for a long time. Smokers who are unavoidable, such as those who have a habit of smoking within 15 minutes after waking up. Smokers are administered at an effective dosage, eg, per dose of theanine, sufficient to suppress the need for smoking, in the wake, preferably from 0.02 to 10 mg / kg body weight, more preferably from 0.2 to 10 mg / kg body weight, more More preferably 0.8 to 10 mg / kg body weight. On the other hand, if a smoker wishes to eradicate smoking habits, effective per dose of theanine sufficient to suppress the desire for smoking, preferably for at least about 3 hours, more preferably for about 5 hours, when the smoking desire begins It is preferred to administer in dosage, which is preferably from 0.02 to 10 mg / kg body weight, more preferably from 0.2 to 10 mg / kg body weight, even more preferably from 0.8 to 10 mg / kg body weight.

However, since there is a difference in smoking habit or withdrawal symptoms (eg, age, sex) among individuals, the theanine dosage of the present invention is not particularly limited to the above range. The dose of theanine can be appropriately adjusted according to the condition of each smoker and the desired level of effect. The frequency and interval of administration may also be appropriately selected.

In still another embodiment of the present invention, the present invention provides the use of theanine to prepare a drug for preventing, alleviating or eliminating withdrawal symptoms caused by smoking cessation or insulation.

The composition of the present invention is based on the smoking desire inhibitory action first shown for theanine. Theanine is known as the main component of the flavor of tea and has been used as a food additive for its flavor. For its stability, there is no fatality in acute toxicity testing with mice administered orally at 5 g / kg body weight and no abnormalities in general condition and body weight. There is no restriction on the amount of addition based on the food hygiene law. In addition, unlike conventional nicotine preparations, since there is no dependency, the composition of the present invention can safely and effectively suppress the smoking desire.

Disclosure of the Invention

The object of the present invention is to provide a high level of safety in order to (1) suppress smoking urges in situations where smoking cessation is necessary in everyday life, (2) intentionally (freely) quit or insulate, and (3) eradicate smoking habits. To provide a smoking desire suppressing composition, there is no dependency. Another object of the present invention is to provide a smoking cessation or insulation method comprising administering a theanine-containing composition to an individual.

As a result of research to solve the above problems, the present inventors found that theanine is effective in suppressing smoking desire, its efficacy is higher than that of the prior art, and theanine prevents, alleviates or eliminates withdrawal symptoms caused by smoking in situations where smoking is necessary. It was found that this can be done, and thus the present invention has been completed.

Specifically, the subject matter of the present invention relates to the following:

(1) a smoking desire suppressing composition comprising theanine, and

(2) A smoking cessation or insulation method comprising administering a theanine-containing composition to an individual.

Hereinafter, the present invention will be further described using examples and test examples, and the scope of the present invention is not limited to the above examples.

Preparation Example 1 Preparation of L-Theanine by Enzymatic Method

225 nmol of L, by allowing 0.3 M glutamine and 1.5 M ethylamine to react in borate buffer (Na ₂ B ₄ O ₇ -NaOH, pH 11) in the presence of 0.3 U glutaminase at 30 ° C. for 22 hours. -Theanine was obtained. In addition, glutamic acid as a byproduct was 20 nmol. Purification of theanine from the reaction mixture was carried out by column chromatography of the reaction mixture using a Dowex 50 × 8 column and a Dowex 1 × 2 column, followed by treatment of the obtained product with ethanol.

First, L-theanine was isolated by subjecting the isolated material obtained by the above purification to an amino acid analyzer and paper chromatography to confirm that the isolated material exhibited the same behavior as the standard material. Moreover, when hydrolyzed the isolated material with hydrochloric acid or glutaminase, glutamic acid and ethylamine were generated at a ratio of 1: 1. Since the isolated material was hydrolyzed by glutaminase, ethylamine appeared to be bound at the γ-position of glutamic acid. In addition, by using glutamic acid dehydrogenase, it was confirmed that glutamic acid produced by hydrolysis had L-form. From the above, the resulting compound was finally confirmed to be L-theanine.

Preparation Example 2 Extraction of L-Theanine from Tea Leaves

10 kg of tea leaves (Camellia sinensis L.) were extracted with boiling water. The obtained extract was then applied to a cationic exchange resin ("Dowex HCR W-2", manufactured by Muromachi Kagaku Kogyo K.K.) and eluted with 1N NaOH. The eluted fraction was applied to activated carbon ("Taiko Kasseitan SG", manufactured by Futamura Kagaku Kogyo K.K) and eluted with 15% ethanol. The obtained elution fraction was concentrated on a RO membrane (manufactured by NITTO DENKO CORPORATION "NTR 729 HF"). The concentrate was then purified by column chromatography. In addition, the purified product was recrystallized to yield 24.8 g of L-theanine.

Example 1 Preparation of Chewable Tablets in L-Theanine Combination

As an example of the composition of the L-theanine combination for suppressing a smoking desire, the following raw materials were mixed according to each composition, and the mixture was granulated. The granulated product was then purified to 1.5 g, per tablet, to prepare chewing tablets of L-theanine combination.

71.67% by weight (1.075 g) per granule

Trehalose 10.00% by weight (0.150 g)

L-theanine ("SUNTHEANINE", manufactured by Taiyo Kagaku Co., Ltd.)

13.33% by weight (0.200 g)

Sucrose fatty acid ester

1.00 wt.% (0.015 g)

Spices (manufactured by TAKASAGO INTERNATIONAL CORPORATION)

4.00% by weight (0.060 g)

Total 100% by weight (1.500 g)

Example 2 Preparation of Chewable Tablets in L-Theanine Combination

As an example of the composition of the L-theanine combination for suppressing a smoking desire, the following raw materials were mixed according to each composition, and the mixture was granulated. The granulated product was then purified to 1.5 g, per tablet, to prepare chewing tablets of L-theanine combination.

68.34 weight% (1.025 g) per granule

Trehalose 10.00% by weight (0.150 g)

L-theanine ("SUNTHEANINE", manufactured by Taiyo Kagaku Co., Ltd.)

13.33% by weight (0.200 g)

3.33% caffeine (0.050 g)

Sucrose fatty acid ester

1.00 wt.% (0.015 g)

Spices (manufactured by TAKASAGO INTERNATIONAL CORPORATION)

4.00% by weight (0.060 g)

Total 100% by weight (1.500 g)

Example 3: Preparation of Chewing Gum in L-Theanine Combination

As an example of the composition of L-theanine combination for suppressing a smoking desire, the following raw materials were mixed according to each composition, and chewing gum was produced.

Gum base 20.0 wt% (0.7 g)

Ground sugar

74.3 wt.% (2.6 g)

L-theanine ("SUNTHEANINE", manufactured by Taiyo Kagaku Co., Ltd.)

5.7 weight% (0.2 g)

Total 100.0% by weight (3.5 g)

The above mentioned raw materials are mixed and kneaded until the mixture is homogeneous. While maintaining the temperature at 50 ° C., the obtained kneaded product was extruded in the form of a sheet by an extruder and pressed into a sheet having a predetermined thickness as a pressure roller. The sheet was cut to a size of 20 mm x 75 mm to produce a chewing gum of 3.5 g of L-theanine combination per piece.

Example 4 Preparation of L-Theanine Blended Granules

As an example of a composition of L-theanine combination for suppressing smoking desire, lactose (50 g), L-theanine (10 g), caffeine (3 g), fragrance (2 g, manufactured by TAKASAGO INTERNATIONAL CORPORATION), vitamin C (15 g) and starch (20 g) were mixed and granulated to give L-theanine blended granules, whereby each granule was packed and packed to 2 g per package.

Example 5 Preparation of L-Theanine Blended Powdered Beverages

As an example of a composition of the L-theanine combination for suppressing smoking desire, powdered green tea (50 g), L-theanine (10 g), sugar powder (20 g), vitamin C (10 g) and citric acid (1 g) ) Were mixed and granulated to obtain L-theanine blended powdered beverages, whereby each powdered beverage was packed and packed to 2 g per package.

Example 6 Preparation of L-Theanine Blended Chocolate

As an example of a composition of L-theanine combination for suppressing smoking desire, cacao lump (60 g), L-theanine (0.5 g), trehalose (9 g), glycerol fatty acid ester (0.9 g), whole milk powder (10 g), and vegetable oil (10 g) were mixed and granulated to obtain L-theanine blended chocolate by conventional bapup.

Example 7 Preparation of L-Theanine Blended Beverage

As an example of a composition of the L-theanine combination for suppressing smoking desire, fructose (10 g), muscat fruit juice (1 g), vitamin C (2 g), L-theanine (0.4 g) and citric acid (1 g) was dissolved in 1 liter of water. The obtained mixture was filled into cans at 350 g per can, and then sterilized to prepare a L-theanine blended beverage.

Comparative Example 1: Preparation of Control Chewable Tablets

The raw materials given below were mixed according to each composition, and the mixture was granulated. The granulated product was then tableted to 1.5 g, for each tablet, to prepare a control chew tablet.

85.00 wt.% (1.275 g) per granule

Trehalose 10.00% by weight (0.150 g)

Sucrose fatty acid ester

1.00 wt.% (0.015 g)

Spices (manufactured by TAKASAGO INTERNATIONAL CORPORATION)

4.00% by weight (0.060 g)

Total 100% by weight (1.500 g)

Comparative Example 2: Preparation of Control Chewing Gum

The raw materials given below were mixed according to each composition to prepare a control chewing gum.

Gum base 20.0 wt% (0.7 g)

Sugar powder 80.0 wt% (2.8 g)

Total 100.0% by weight (3.5 g)

The above mentioned raw materials are mixed and kneaded until the mixture is homogeneous. While maintaining the temperature at 50 ° C., the obtained kneaded product was extruded in the form of a sheet by an extruder and pressed into a sheet having a predetermined thickness as a pressure roller. The sheet was cut to a size of 20 mm x 75 mm, producing 3.5 g of control chewing gum per piece.

Test Example 1: Nicotine dependence relaxation test

(1) Subject Selection

To select subjects with high nicotine dependence, support smokers were subjected to the nicotine dependency test developed by Dr. Fagerstroem (Table 1) (Mayumi ABE, "Kinengairai," Haga Shoten, Tokyo, 1999).

Question answer score How many minutes do you smoke your first cigarette after waking up? 30 minutes or more within 30 minutes 10 Is it very difficult to refrain from smoking in non-smoking facilities such as cars, libraries and theaters? Yes No 10 Which cigarettes are the hardest to quit? Morning first cigarette 10 How many cigarettes do you smoke per day? 15 or less 16 to 25 or more 26 or more 012 Do you smoke more in the morning? Yes No 10 Do you smoke when you are sick and lie down all day? Yes No 10 What is the nicotine content of normal tobacco? 0.9 mg or less 1.0 to 1.2 mg 1.3 mg or more 012 Do you suck deeply? Never at all times Always 012

The level of nicotine dependence is assessed according to the following criteria by summing the scores in the above mentioned tests:

Evaluation standard

0-3 points: low dependency level

4 to 5 points: medium dependency level

6 or more points: High dependency level

(2) short-term nicotine dependence relaxation test

When a smoker is classified as a change in blood nicotine concentration within one day, as shown in Fig. 1, the smoker is (a) peak-seeker type and (B) trough-maintainer. Can be classified as a type. Peak-seeker type smokers are generally seen in so-called “heavy smokers” who continue to smoke to avoid lowering nicotine levels in the blood. Nicotine accumulates in the body, reaching a predetermined level by afternoon. Tro-maintainer type smokers, on the other hand, are those who regularly seek smoking stimuli, and the number of cigarettes they smoke is small. Peaks in blood nicotine concentration are clearly found. In this test, in order to study the inhibitory effect of smoking desire by theanine, it was tested in the state immediately after the wake up with the lowest nicotine concentration in the body (tests 1 and 2 immediately after the weather). In addition, as seen in the peak-seeker smokers, the test was conducted in the afternoon when the nicotine concentration presumably reached the highest level of the day (daytime test). In addition, the effect of continuous intake within 1 day was also studied. Specifically, whether the time until the smoker takes his first cigarette after waking can be significantly extended by the intake of theanine, whether the smoking interval time of the day can be significantly extended by ingestion, and their smoking cigarettes It was studied whether the number of babies was significantly reduced by ingestion.

(i) Test immediately after waking up 1

1) test

In the item (1) above, 50 subjects (average weight: 73 kg) among the subjects having a moderate level of dependency and a habit of smoking within 15 minutes of waking up were selected and tested. In the test, they ingested the test substances listed in Table 2 immediately after waking up (within about 15 minutes of waking up) and recorded the time from the ingestion of the test substance to the first tobacco piggy (time before smoking).

The subjects were divided into five groups (10 in each group), and each subject was consumed from any of the test substances listed in Table 2 assigned to each group daily from Monday to Friday, and pre-smoking. The time was measured. The average time for each test substance was calculated based on the data of the pre-smoking time obtained, and they were shown as the pre-smoking time in Table 2, respectively.

During the test period, each subject did not know which of the subjects had taken. During the test period, except for the ingestion of the test substance immediately after waking up, no restrictions were placed on their lives including smoking.

Test substance Time before smoking Chewing Tablets of L-Theanine Combination of Example 1 3 hours ± 30 minutes Chewable Tablets of L-Theanine Combination of Example 2 3 hours ± 30 minutes Chewing Gum of the L-Theanine Combination of Example 3 2.5 hours ± 30 minutes Control Chewing Tablets of Comparative Example 1 40 minutes ± 15 minutes Control Chewing Gum of Comparative Example 2 40 minutes ± 15 minutes

2) results

As shown in Table 2, in the group in which the test substances of Comparative Examples 1 and 2 were ingested, the time before smoking was short, and thus a smoking desire suppressing effect could not be found. On the other hand, in the group ingesting the test substance of Examples 1 to 3, the time from the ingestion of the test substance to the first cigarette was significantly prolonged, thereby confirming the effect of suppressing smoking desire.

(ii) Test 2 immediately after waking up

1) subject

According to the nicotine dependency test of item (1) above, the subjects were preliminarily investigated and 23 subjects (mean body weight: 68 kg) having a medium level or higher dependency were selected. The subject was a male of 31 to 59 years of age who has been smoking for 10 to 40 years.

2) preliminary investigation

Prior to conducting the test, subjects were allowed to wake up on the survey chart for two days each on holidays and weekdays until they got to sleep, and (1) smoked cigarettes / day, (2) weather The time until after first smoking, and (3) the mean smoking interval time were examined beforehand.

3) test

As theanine, L-theanine (trade name "SUNTHEANINE", manufactured by Taiyo Kagaku Co., Ltd.) of food additive grade (purity: 99% or more) was used. The compositions of the test substance (Example 8) and placebo (Comparative Example 3) are shown in Table 3. Theanine content was 200 mg and replaced theanine with lactose in placebo. The shape was a troche-type tablet (φ15 mm × 7 mm) in order to remain in the mouth for about 5 minutes.

Raw material Test substance Placebo Sucrose 1.015 g 1.015 g Trehalose 0.150 g 0.150 g L-Theanine (trade name "SUNTHEANINE", manufactured by Taiyo Kagaku Co., Ltd.) 0.200 g 0.000 g Lactose 0.000 g 0.200 g Lubricants (polyglycerol fatty acid esters) 0.015 g 0.015 g Powder spices 0.120 g 0.120 g sum 1.500 g 1.500 g

Two tablets of test substance and two tablets of placebo were given to each subject, and one tablet was taken daily to carry out the test for a total of four days according to the double blind law. Each of each test substance and placebo was taken within 15 minutes of waking up. Subjects were allowed to refrain from smoking until the moment when they could no longer control their smoking desire after ingestion. Subjects were asked to record the time of waking up, the time of ingestion of the test substance or placebo, and the total smoking time of the day in the survey chart.

4) Results

The results of a preliminary survey of the number of cigarette cigarettes smoked for 23 subjects and the time to first cigarette after waking are shown in FIG. 2. About 74% of the subjects smoked more than 21 cigarettes a day, and about 83% of the subjects smoked their first cigarette of the day within 30 minutes of waking up. This group was supposed to be a soldier with relatively strong nicotine dependence.

The test results are shown in FIG. The test was conducted in two groups, the group of all subjects and the group of subjects who smoked within 30 minutes of waking up. The theanine-containing test substance had a greater smoking inhibitory effect than the placebo-containing test substance, indicating that there was a smoking inhibitory effect of 2 hours or more after ingestion. The placebo and test subject groups differed significantly from each other. Here, it was tested by the student paired t-test.

(iii) daytime testing

1) subject

As the subject, 39 subjects (average body weight: 70 kg) were selected from the same participants as in the test 2 (ii) item immediately after the wake up. Subjects were 26 to 59 years old, had a smoking history of 3 to 40 years, and included one woman.

2) preliminary investigation

Prior to the test, a preliminary investigation was carried out in the same manner as in Test 2 (ii) immediately after the gas phase.

3) test

As theanine, test substances and placebos, which are the same as those in Test 2 (ii) immediately after the gas phase, were used. The test was conducted for a total of four days of week, with no business trips or even short office outings.

Two tablets of test substance and two tablets of placebo were distributed to each subject, and the tablets were taken in the designated order to conduct the test according to the double blind law. During the morning of the test, the subject was allowed to smoke freely. Each test substance and placebo were taken within 30 minutes of the last smoking prior to beginning the afternoon work and subjects were allowed to refrain from smoking until the moment they could no longer control their smoking desire. Subjects were asked to record the smoking time in the morning, the intake time of the test substance or placebo, and the total smoking time in the afternoon on the survey chart.

4) Results

The results of a preliminary survey of the number of cigarette cigarettes smoked and the mean smoking interval time for 39 subjects participating in the daytime trial are shown in FIG. 4. The number of cigarette cigarettes per day was between 10 and 40. Therefore, this test was performed on two groups, the group of all subjects, and the group of subjects with relatively high nicotine dependence, with more than 21 blood per day (FIG. 5).

Theanine-containing test substances have a longer average smoking interval time than the placebo-containing test substances, thus revealing a smoking inhibitory effect compared to the placebo. In addition, the test substance group statistically showed a significant difference to the Plasbo group in both groups. Here, it was tested by the student paired t-test.

(iv) 1 day continuous intake test

1) subject

As the subject, one subject (weight: 74 kg) was selected from the same participants as in Test 2 (ii) immediately after waking up, which was judged to have a high level of dependence according to the nicotine dependency test. Subject was a 36 year old male with 17 years of smoking experience.

2) test

As theanine and the test substance, the same ones as in Test 2 (ii) immediately after the gas phase were used. Three repeated trials were performed within one day. That is, the test was conducted on three different days. Subjects were asked to take ad libitum , a test substance, whenever the desire to smoke occurred during the period from wake up to 8 pm. Subjects were also allowed to smoke freely during that time. Subjects were asked to record all smoking times and ingestion times of the test substance during the day in the survey chart.

3) results

FIG. 6 is a graph showing the relationship between the number of cigarettes smoked and the number of intakes of a test substance when the test substance is ingested every time a smoking desire occurs during the period from the weather to 8 pm, wherein the test subject is about 40 days a day. I smoked Gaby. The daily intake of test substances was on the order of 7 to 8 tablets, while the number of cigarette cigarettes smoked was clearly reduced. In particular, no side effects were found.

(3) long-term nicotine dependency relaxation test

Inhibition of smoking desire by long term theanine intake was studied by (i) one week continuous intake and (ii) one month continuous intake.

(i) 1 week continuous intake

1) subject

As the subject, one subject (weight: 75 kg) was selected from the same participants as in Test 2 (ii) immediately after waking up, which was judged to have a high level of dependence according to the nicotine dependency test. Subject was a 51 year old male and had 33 years of smoking experience.

2) test

As theanine and the test substance, the same ones as in Test 2 (ii) immediately after the gas phase were used. The test was run for one week. Subjects were asked to take ad libitum , a test substance, whenever a desire to smoke occurred. Subjects were also allowed to smoke freely during that time. Subjects were asked to record all smoking times and ingestion times of the test substance within a week on the survey chart.

3) results

7 is a graph showing the relationship between the number of cigarettes smoked per day and the number of intakes of test substances. The daily intake of the test substance was about 2 tablets, whereas subjects who wanted to quit smoking on the basis of this test quit smoking on the 5th day and thereafter after taking 1 definition of the test substance, and consequently 1 week after the start of ingestion. Successfully quit smoking. After that, smoking was continued even after half a year even if little theanine was consumed. Here, the test substance was not taken on day 1.

(ii) 1 month continuous intake test

The effect of chewing tablets of the L-theanine combination obtained in Example 2 was carried out on 30 subjects (mean body weight: 70 kg) judged to be at least moderate in the subject's selection under item (1) above. It was evaluated by the intake test. As a comparison, the control chew tablet of Comparative Example 1 was also tested.

Two divided groups of 15 subjects each were tested. In each group of subjects, chew tablets (smokers No. 1 to 15) of the L-theanine combination of Example 2, or control chew tablets (smokers No. 16 to 30) of Comparative Example 1 were taken at intervals of 5 hours or more. And in the evening, the intake was continued for 1 month by ingesting 2 tablets of 1 tablet each day. During the test period, each subject was not informed of the substance ingested. In addition, except for taking the test substance within one day, there were no special restrictions on life including smoking.

The questionnaire was examined for changes in the average number of cigarettes smoked before and after the test, and the effects of the test substances were evaluated according to the following evaluation criteria. The results are shown in Table 4.

Evaluation standard

◎: smoking effect (the number of cigarettes smoked: 0)

○: suppression of smoking desire (number of cigarettes smoked: less than 10 cigarettes)

△: slight smoking desire suppression effect (the number of cigarettes smoked: 5 to 9 reductions)

×: no effect (the number of cigarettes smoked: other than the above)

According to the results shown in Table 4, the chewable tablets of the L-theanine combination of Example 2 were found to have a smoking cessation effect or a smoking desire suppressing effect in all cases. On the other hand, the control chew tablet prepared in Comparative Example 1 was found to have little such effect. Here, subject No. 3, No. 6, No. 13, No. 16 and No. 27 were those who wanted to quit smoking because of this test. Subject No. using a control chew tablet prepared in Comparative Example 1. 16 and No. 27 slightly reduced the number of cigarette cigarettes smoked, but could not achieve smoking cessation.

Incidentally, during this test period, no adverse side effects were found at all, and no dependence on the test substance was confirmed.

Test Example 2

When chewing tablets of L-theanine combination are applied to oral mucosal absorption or intestinal absorption, a test is performed for changes in the concentration of theanine in the blood. Subjects were not allowed to consume any food other than water, and quit smoking after waking up.

(1) oral mucosa absorption test

(i) Theanine intake: 87 mg

1) subject

As a subject, a test was conducted on a smoker with high nicotine dependence [smoker A (average weight: 78 kg)] among the same participants as in Test 2 (ii) immediately after waking up.

2) test

As theanine and the test substance, the same ones as in Test 2 (ii) immediately after the gas phase were used. However, the test substance was taken in half (theanine content: 87 mg).

150 minutes after the subject A wakes up, the test substance is ingested in the mouth. In addition, subjects were allowed to refrain from smoking for 150 minutes after waking up. Blood was collected before ingesting the test substance, and also after 5 minutes, 10 minutes, 20 minutes, 30 minutes, 60 minutes, 90 minutes, and 180 minutes after ingestion. During the test, subjects were asked to record their smoking desires according to the criteria listed in Table 5.

Evaluation standard 0 One 2 3 4 Degree No desire to smoke There is a slight desire to smoke There is a little need for smoking Moderate smoking desire In high degree of smoking desire

Here, blood theanine concentration was measured by the following method.

(Measurement of Theanine Concentration in Blood)

(a) pretreatment of blood

Each collected blood was distributed to blood vessels (Venoject II Autosep, TERUMO CORPORATION) and centrifuged (3000 rpm, 10 minutes, himac CT 6D: Hitachi Koki Co., Ltd.) to collect serum. To 0.5 ml of each obtained serum, 1.0 ml of acetonitrile was added and the mixture was centrifuged (12000 rpm, 10 minutes, MR-150: K.K. Tommy Seiki) to collect the supernatant. The obtained supernatant is dried with a centrifugal evaporator (model "CVE-100D", Tokyo Rika Kikai K.K.), and 0.5 ml of distilled water is added to the obtained material to dissolve it.

(b) Analysis of Theanine

Serum theanine concentrations were measured according to the AccQTag amino acid assay of Waters Corporation. 10 microliters of blood pretreated by filtration with a membrane filter (DISMIC 13CP: ADVANTEC), 10 μl of 10 ppm norleucine, an internal standard reagent, 60 μl of AccQ Fluoroborate buffer (Waters Corporation) and 20 μl of AccQ. Fluorine reagents (Waters Corporation) were mixed together and then an induction reaction was carried out. Samples were analyzed by an AccQ · Tag amino acid analysis column (3.9 mm × 150 mm: Waters Corporation) and detected by fluorescence spectroscopy at excitation wavelength 250 nm and emission wavelength 395 nm. Quantification was carried out by a calibration curve method.

(ii) Theanine intake: 200 mg

As the test chew tablet, the chew tablet of the L-theanine combination of Example 1 containing 200 mg of L-theanine was used. This test was conducted on smokers who exhibit high nicotine dependence [subject A as in the case of item (i) theanine 87 mg intake above]. Subject A was allowed to take one tablet of chewing tablets of Example 1 while being awake for 150 minutes after waking up for 6 minutes. In addition, subjects were allowed to refrain from smoking for 150 minutes after waking up. Blood was collected before the chewing tablet intake of Example 1, and also after 5 minutes, 10 minutes, 20 minutes, 30 minutes, 60 minutes, 90 minutes, and 180 minutes after ingestion. During the test, the presence, absence, and extent of smoking desires were queried according to the criteria shown in Table 5, and withdrawal symptoms were observed. Here, blood theanine concentration was measured in the same manner as in the case of the intake of 87 mg of theanine above item (i).

(2) enteric absorption test

In the intestinal absorption test, the non-smoker (subject B) was tested and immediately chewed and swallowed one chewable tablet of Example 1 150 minutes after waking up to subject B. Blood was collected before the chewing tablet intake of Example 1, and also after 5 minutes, 10 minutes, 20 minutes, 30 minutes, 60 minutes, 90 minutes, and 180 minutes after ingestion. Here, blood theanine concentration was measured in the same manner as in the case of the intake of 87 mg of theanine above item (i).

Test result :

The change in serum theanine concentration (ppm) over time when the chewing gum of the L-theanine combination (theanine content: 200 mg) is absorbed in the oral mucosa or intestine is shown in FIG. 8. Comparing the intraoral mucosal absorption and the intestinal absorption, it can be seen that the time to reach the maximum blood theanine concentration is shorter in the oral mucosal absorption, and thus faster in the oral mucosal absorption. In addition, it can be seen from the fact that the maximum value of theanine concentration in blood is higher in oral mucosal absorption, the oral mucosal absorption shows a good rate of absorption. However, blood theanine concentrations lasted longer in intestinal absorption.

In addition, in the above item (1) oral mucosal absorption test, the smoking desire before, during and after the test was monitored over time as mentioned above. Changes in smoking desires over time, and changes in blood theanine concentrations when ingesting theanine in an amount of 87 mg and ingesting theanine in an amount of 200 mg are shown in FIGS. 9 and 10, respectively.

As shown in FIG. 9, Subject A's need for smoking was monitored over time before, during and after the test. Immediately before ingesting the test substance, the subject was allowed to refrain from smoking for 150 minutes after waking up, causing a strong need for smoking and moderate withdrawal symptoms. However, after ingestion, the desire for smoking disappeared rapidly, after which the change in smoking desire was almost suppressed in a blood theanine concentration-dependent manner. Compared with the theanine 200 mg intake, the theanine concentration in the blood is lower with the intake of 87 mg of theanine, so the smoking desire is relatively high from the start of the test, the smoking desire appears after 60 minutes, and the desire to be suppressed after 140 minutes. Can't, and smokers smoke. As a result, the subject did not smoke for 290 minutes after waking up. On the other hand, as shown in FIG. 10, in the case of intake of 200 mg of theanine, the smoking desire of Subject A was monitored over time before, during and after the test. Immediately before taking chewable tablets of l-theanine combination, subjects were allowed to refrain from smoking for 150 minutes after waking up, resulting in a strong need for smoking and moderate withdrawal symptoms. However, after ingestion, the desire for smoking disappeared rapidly, and then with some change, the change in smoking desire was almost suppressed in a blood-theanine concentration-dependent manner. The desire for smoking appeared 150 minutes after the start of the test, and the subject finally smoked at 165 minutes. As a result, the subject did not smoke for 315 minutes after waking up. Subject A usually had a habit of smoking immediately after waking up, but it was found that his smoking desire can be effectively suppressed by taking about 90 to about 200 mg of theanine. In addition, the inhibitory effect was speculated to be related to changes in theanine concentrations in the blood.

Summary of Test Examples 1 and 2

In the short-term nicotine-dependent relaxation test, the test was performed immediately after wake-up, with presumably lowest levels of nicotine in the body, and during daytime, with presumably high levels of nicotine in the body. In any case, in subjects whose nicotine dependence was judged to be at or above moderate levels, theanine (200 mg) ingestion showed a significant inhibitory effect on smoking. In particular, the "daytime test" was performed at the working site. There may be various factors (noise) that induce smoking, but the effect of theanine could be confirmed. In addition, also in the continuous intake in the day performed, the theanine intake effect was tested in daily life, at which time there was a significant decrease in the number of cigarette cigarettes smoked.

In addition, long-term nicotine dependence-relieving trials showed that in some cases, subjects were able to quit smoking, even with continuous intake of about 400 mg theanine per day. During one month of continuous intake, smoking cessation effects or smoking desire suppression effects were found in all intakers. There were also no undesirable side effects or theanine dependencies.

On the other hand, in the oral mucosal absorption test and intestinal absorption test, theanine was absorbed more rapidly through the oral mucosa, the absorption rate was higher, and the inhibitory effect on the smoking desire by theanine was higher than the intestinal absorption. Appeared to be associated with.

From the above, according to the theanine-containing smoking desire inhibiting composition of the present invention, even for smokers with a moderate or higher nicotine dependency level, the smoking desire can be significantly suppressed by ingestion of the composition, thereby intentionally (freely) quitting smoking or insulating, And it can be seen that the eradication of smoking habit can be achieved safely and effectively. It can also be seen that theanine intake is more effective by being performed with a composition suitable for absorption through the oral mucosa as described in detail herein.

According to the present invention, (1) suppressing the need for smoking in a situation where quitting smoking is necessary for daily life; (2) intentional smoking cessation or insulation (freely); And (3) a smoking desire suppressing composition that exhibits an excellent effect that eradication of smoking habits can be performed safely and effectively.

Claims (15)

A smoking desire suppressing composition comprising theanine. The composition of claim 1 for preventing, alleviating or eliminating withdrawal symptoms caused by smoking cessation or insulation. The composition of claim 1 or 2, wherein the composition is pre-administered to the individual when withdrawal symptoms are predicted to be caused by smoking cessation or isolation. The composition of claim 1 or 2, which is administered to the individual during the onset of withdrawal symptoms due to smoking cessation or insulation. The method of claim 1 or 2, wherein the tablets, candies, chocolates, gums, crackers, biscuits, cookies, paste products, processed soy products, mousse, jelly, yoghurt, cold confections are suitable for absorption through the oral mucosa. , Cakes, breads, concentrated juices, concentrated reduced juices, fresh juices, mixed fruit juices, fruit juices with fruit kernels, fruit juices, fruit / vegetable juices, vegetable juices, carbonated drinks, soft drinks, mineral water, milk, The composition is in the form selected from the group consisting of milk beverages, favorite beverages and alcoholic beverages. 6. The composition of claim 5 in the form of a tablet, candy or gum, which can remain in the mouth for at least 3 minutes when ingested orally. The composition of claim 1 or 2, which is a food composition. delete delete delete delete delete delete delete delete